Publications
Specialty
Search
Oncology
10/01/2024
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for patients with extensive-stage small cell lung cancer.
Journal of Clinical Pathways
10/01/2024
"...the self-service approach to data access enables health systems to empower clinicians and administrators by allowing them to have a dialogue with their own data. It also offers the potential for significant savings in time and resources," said Daniel Blumenthal, VP of Strategy, MDClone
Advances in Inflammatory Bowel Disease Network, Gastroenterology
10/01/2024
Early detection and treatment are the keys to reducing risk of progressive disease.
Oncology
10/01/2024
According to updated data from the phase 2 PHAROS trial, encorafenib plus binimetinib showed prolonged efficacy, particularly among treatment-naïve patients, for BRAF V600E-mutant metastatic non-small cell lung cancer.
Wound Care
10/01/2024
A 200-patient RCT will evaluate the role of local 4-aminopyridine (4-AP) on the treatment of burn wounds to accelerate healing with primary outcome of healing rate up to 12 months. Not yet recruiting; estimated study completion is Sept 2028. clinicaltrials.gov
Wound Care
10/01/2024
A study of 80 nondiabetic laparotomy patients compared those who were treated with NPWT vs conventional dressing and found that the overall occurrence of SSIs within the 30-day follow-up period was significantly lower in the NPWT group, but no difference was observed in LOS or scarring. Cureus
Wound Care
10/01/2024
Tides Medical announced an expansion of its portfolio with the launch of APLICOR 3D, a personalized medicine option that integrates advanced AI and 3D printing using a patient’s adipose tissue. Tides has an exclusive partnership with ROKIT Healthcare of S Korea.
Wound Care
10/01/2024
Spectral AI announces it has achieved 25% of patient enrollment at emergency depts (EDs) for its US Burns Pivotal Study and added 2 more clinical sites, expanding to 11 ED facilities. The company plans to pursue a De Novo submission for DeepView as a Class II medical device in Q225.
Wound Care
10/01/2024
A 40-patient RCT will examine the effectiveness and safety of a topical HMMSF gel for the treatment of DFUs during the granulation growth phase with the primary outcome of wound area reduction rate of up to 2 weeks. Not yet recruiting; the estimated study completion is May 2026. clinicaltrials.gov
Wound Care
10/01/2024
Med Way Inc received FDA 510(k) clearance for V-Move and V-Grand NPWT products indicated for chronic, acute, traumatic, subactute, dehisced wounds, partial-thickness burns, ulcers, flaps and grafts using extriCare 3600 and VCare 10000-300S pump as predicates.
Wound Care
10/01/2024
Convatec is progressing in generating and disseminating clinical evidence for InnovaMatrix AC. Results from the 1st phase of its RWE, including VLUs, DFUs and other indications, will be published in H224 and H125. Its 120-patient clinical study for VLUs is currently recruiting patients.
Wound Care
10/01/2024
A study of lower extremity lymphedema in 143-patients at the VA found that using advanced pneumatic compression devices (Flexitouch) improved all domains of QoL score after 12 weeks of treatment and through a 52-week follow-up. JVS-VL
Psych Congress Network
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
Wound Care
10/01/2024
In an interview with SmartTRAK, Dr. Willi Schnorpfeil, an expert in reimbursement strategies, offers a comprehensive overview of the regulatory changes for advanced wound care products in Germany, which pose a potential threat to both market stability and patient care.
Oncology
10/01/2024
What is your primary treatment goal when treating your patients with MF?
Oncology
10/01/2024
Managing for the risk of thrombosis is a key treatment goal for patients with PV. When it comes to managing for the risk of thrombosis, which counts are you most concerned about?
Oncology
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete res
Cath Lab Digest, CardioVascular
10/01/2024
Drs Qavi and Sengodan share a successful radial access intervention in a retroflexed left circumflex artery lesion with challenging subclavian anatomy.
First Report Managed Care
10/01/2024
From cost-cutting to value creation, learn how payment integrity is shifting towards a more holistic approach in the health care industry to enhance care quality and stakeholder relationships.
Oncology
10/01/2024
Georgina Long, MD, PhD, discusses updated pooled analysis results from the International Neoadjuvant Melanoma Consortium which identified that neoadjuvant immunotherapy extends survival in patients with advanced melanoma.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
